This document is an updated guideline and details the recommendations for the front‐line management of adult patients with an established diagnosis of post‐transplant lymphoproliferative disorder (PTLD) following solid organ transplantation (SOT).
Post‐transplant lymphoproliferative disease represents a spectrum of disorders resulting from lymphoid proliferations that occur as a result of immunosuppression following SOT. Lymphoproliferative disorders account for 21% of all cancers of SOT recipients, as compared with 4–5% within the immunocompetent population.1 In adult SOT recipients, PTLD is a common malignancy after skin cancer and is associated with a significant cancer‐related mortality.1 The reported incidence varies according to patient age, transplant type and the degree of immunosuppression. Historically, PTLD has been reported to occur most frequently in the first year following transplantation.2-4 However, these studies also report a similar incidence of PTLD beyond one year, suggesting the late occurrence is as prevalent post SOT.2-5
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.